Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

NCT04884763 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Temporomandibular Disorder

Interventions

DRUG: Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
DRUG: Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments

Sponsor

Indiana University

Collaborators

[object Object]